Prion-like mechanisms in alzheimer's disease

Current Alzheimer Research

Volumn 11, Issue 8, 2014, Pages 755-764

  Yin, Rui Hua ^a   Tan, Lan ^a,b,c   Jiang, Teng ^b   Yu, Jin Tai ^a,b,c  

^a QINGDAO UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Alzheimer's disease; Prion like mechanism; Tanscellular propagation; Tau proteins; Templated conformational change; amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN; PRION PROTEIN; TAU PROTEIN; PRION;

ALZHEIMER DISEASE; ARTICLE; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; PATHOPHYSIOLOGY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; WEB OF SCIENCE; AMYLOID PLAQUE; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; PRION; PROTEIN CONFORMATION; PROTEIN TRANSPORT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; PLAQUE, AMYLOID; PRIONS; PROTEIN CONFORMATION; PROTEIN TRANSPORT; TAU PROTEINS;

EID: 84922716198     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501108140910121425     Document Type: Article

References (87)

1. Magalhaes AC, Baron GS, Lee KS, Steele-Mortimer O, Dorward D, Prado MA, et al. Uptake and neuritic transport of scrapie prion protein coincident with infection of neuronal cells. J Neurosci 25(21): 5207-16 (2005).
2. Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, Budka H, et al. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathologica 119(2): 177-87 (2010).
3. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 33(3): 1024-37 (2013).
4. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284(19): 12845-52 (2009).
5. Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286(17): 15317-31 (2011).
6. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biol 11(7): 909-13 (2009).
7. Stohr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, et al. Purified and synthetic Alzheimer's amyloid beta (Abeta) prions. Proc Natl Acad Sci USA 109(27): 11025-30 (2012).
8. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330 (6006): 980-2 (2010).
9. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, Hallbeck M. Spreading of neurodegenerative pathology via neuronto- neuron transmission of beta-amyloid. J Neurosci 32(26): 8767-77 (2012).
10. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14(5): 504-6 (2008).
11. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, et al. Alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121(2): 715-25 (2011).
12. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 72(4): 517-24 (2012).
13. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinsonlike neurodegeneration in nontransgenic mice. Science 338(6109): 949-53 (2012).
14. Trevino RS, Lauckner JE, Sourigues Y, Pearce MM, Bousset L, Melki R, et al. Fibrillar structure and charge determine the interaction of polyglutamine protein aggregates with the cell surface. The J Biol Chemi 287(35): 29722-8 (2012).
15. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Bio 11(2): 219-25 (2009).
16. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 108(9): 3548-53 (2011).
17. Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A seeding reaction recapitulates intracellular formation of Sarkosylinsoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem 286(21): 18664-72 (2011).
18. Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and Etiology of Alzheimer's disease: From Genetic to Non- Genetic Factors. Curr Alzheimer Res 10(8): 852-67 (2013).
19. Jiang T, Yu JT, Tan L. Novel disease-modifying therapies for Alzheimer's disease. Journal of Alzheimer's disease: JAD 31(3): 475-92 (2012).
20. Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet 47: 601-23 (2013).
21. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 216(4542): 136-44 (1982).
22. Poggiolini I, Legname G. Mapping the prion protein distribution in marsupials: insights from comparing opossum with mouse CNS. PloS one 7(11): e50370 (2012).
23. Yu H, Liu X, Neupane K, Gupta AN, Brigley AM, Solanki A, et al. Direct observation of multiple misfolding pathways in a single prion protein molecule. Proc Natl Acad Sci USA 109(14): 5283-8 (2012).
24. Kaufman SK, Diamond MI. Prion-like propagation of protein aggregation and related therapeutic strategies. Neurotherapeutics 10(3): 371-82 (2013).
25. Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 147(3): 498-508 (2011).
26. Aguzzi A. Cell biology: Beyond the prion principle. Nature 459(7249): 924-5 (2009).
27. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64(6): 783-90 (2009).
28. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11(4): 301-7 (2010).
29. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336(6088): 1511-3 (2012).
30. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70(4): 532-40 (2011).
31. Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron 73(6): 1204-15 (2012).
32. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73(6): 1216-27 (2012).
33. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature reviews Drug discovery 10(9): 698-712 (2011).
34. Jarrett JT, Lansbury PT, Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73(6): 1055-8.(1993).
35. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int J Exp Pathol 74(5): 441-54 (1993).
36. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, et al. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. Neurosci 20(10): 3606-11 (2000).
37. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 17(12): 1347-53 (2012).
38. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral betaamyloidogenesis is governed by agent and host. Science 313(5794): 1781-4 (2006).
39. Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA 70(3): 304-10 (2013).
40. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307(5707): 262-5 (2005).
41. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M. Soluble Abeta seeds are potent inducers of cerebral betaamyloid deposition. Neurosci 31(41): 14488-95 (2011).
42. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4): 351-7 (1997).
43. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA 106(31): 12926-31 (2009).
44. Kim J, Holtzman DM. Medicine. Prion-like behavior of amyloidbeta. Science 330(6006): 918-9 (2010).
45. Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M. The presence of Abeta seeds, and not age per se, is critical to the initiation of Abeta deposition in the brain. Acta Neuropathologica 123(1): 31-7 (2012).
46. Ronnback A, Sagelius H, Bergstedt KD, Naslund J, Westermark GT, Winblad B, et al. Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiol Aging 33(4): 831 e11-9 (2012).
47. Perez-Gonzalez R, Gauthier SA, Kumar A, Levy E. The exosome secretory pathway transports amyloid precursor protein carboxylterminal fragments from the cell into the brain extracellular space. J Biol Chem 287(51): 43108-15 (2012).
48. Wang Y, Cui J, Sun X, Zhang Y. Tunneling-nanotube development in astrocytes depends on p53 activation. Cell death and differentiation 18(4): 732-42 (2011).
49. Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular highways for intercellular organelle transport. Science 303(5660): 1007-10 (2004).
50. Marzo L, Gousset K, Zurzolo C. Multifaceted roles of tunneling nanotubes in intercellular communication. Frontiers in physiology 3: 72 (2012).
51. Gousset K, Schiff E, Langevin C, Marijanovic Z, Caputo A, Browman DT, et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol 11(3): 328-36 (2009).
52. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-42 (2008).
53. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero- Munoz MJ, Kiritoshi T, Neugebauer V, et al. Alzheimer brainderived tau oligomers propagate pathology from endogenous tau. Scientific reports 2: 700 (2012).
54. Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 284(6): 3546-51 (2009).
55. Wegmann S, Jung YJ, Chinnathambi S, Mandelkow EM, Mandelkow E, Muller DJ. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem 285(35): 27302-13 (2010).
56. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225(4667): 1168-70 (1984).
57. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4): 685-97 (2012).
58. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PloS one 7(2): e31302 (2012).
59. Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuronto- neuron propagation? Acta Neuropathologica 121(5): 589-95 (2011).
60. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathologica 82(4): 239-59 (1991).
61. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurology 12(6): 609-22 (2013).
62. Witter MP. The perforant path: Projections from the entorhinal cortex to the dentate gyrus. Prog Brain Res 163: 43-61 (2007).
63. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. Neuroscience 31(37): 13110-7 (2011).
64. Saman S, Kim W, Raya M, Visnick Y, Miro S, Jackson B, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287(6): 3842-9 (2012).
65. Simon D, Garcia-Garcia E, Gomez-Ramos A, Falcon-Perez JM, Diaz-Hernandez M, Hernandez F, et al. Tau overexpression results in its secretion via membrane vesicles. Neuro-degenerative diseases 10(1-4): 73-5 (2012).
66. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287(23): 19440-51 (2012).
67. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS letters 580(20): 4842-50 (2006).
68. Plouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PloS one 7(5): e36873 (2012).
69. Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis 48(3): 356-66 (2012).
70. Lee S, Kim W, Li Z, Hall GF. Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model. Int J Alzheimers Dis 2012: 172837 (2012).
71. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 37(4): 673-81 (2008).
72. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. The J Biol Chem 288(3): 1856-70 (2013).
73. Avila J. Spreading of Tau Pathology. J Alzheimers Dis Parkinsonism 02(01): (2012).
74. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against beta-amyloid (Abeta) for the treatment of Alzheimer's disease: the Abeta target at a crossroads. Expert Opin Biol Ther 11(6): 679-86 (2011).
75. Liu Y, Lee MK, James MM, Price DL, Borchelt DR, Troncoso JC, et al. Passive (amyloid-beta) immunotherapy attenuates monoaminergic axonal degeneration in the AbetaPPswe/PS1dE9 mice. J Alzheimer's disease 23(2): 271-9 (2011).
76. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimer's disease 28(1): 49-69 (2012).
77. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Ann Rev Neurosci 31: 175-93 (2008).
78. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224(2): 472-85 (2010).
79. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118(4): 658-67 (2011).
80. Zhao M, Wang SW, Wang YJ, Zhang R, Li YN, Su YJ, et al. Panamyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease. Curr Alzheimer Res 11(1): 69-78 (2014).
81. Lahiri DK. Prions: a piece of the puzzle? Science 337(6099): 1172 (2012).
82. Lahiri DK, Maloney B, Zawia NH. The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14(11): 992-1003 (2009).
83. Hu N, Yu JT, Tan L, Wang YL, Sun L, Tan L. Nutrition and the risk of Alzheimer's disease. BioMed Res Intern 2013: 524820 (2013).
84. Tan MS, Yu JT, Jiang T, Zhu XC, Guan HS, Tan L. Genetic variation in BIN1 gene and Alzheimer's disease risk in Han Chinese individuals. Neurobiology Aging 35(7): 1781 e1-8 (2014).
85. Yin RH, Yu JT, Tan L. The Role of SORL1 in Alzheimer's Disease. Mol Neurobiol (2014).
86. Jiang T, Yu JT, Zhu XC, Tan L. TREM2 in Alzheimer's disease. Mol Neurobiol 48(1): 180-5 (2013).
87. Yu JT, Tan L, Hardy J. Apolipoprotein e in Alzheimer's disease: An update. Ann Rev Neurosci 37: 79-100 (2014).